ZUMA-24: A phase 2, open-label study of axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma given outpatient with corticosteroids

Authors

L Leslie
M Tees
Tulio E. Rodriguez, Advocate Aurora HealthFollow
et al

Recommended Citation

Leslie L, Tees M, Flinn IW, et al. ZUMA-24: A PHASE 2, OPEN-LABEL STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA GIVEN OUTPATIENT WITH CORTICOSTEROIDS. Hematological Oncology. 2023;41(S2):843-845. doi:https://doi.org/10.1002/hon.3166_OT23

Affiliations

Advocate Lutheran General Hospital

Type

Abstract